The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.

Gunnar ElkeFrank BloosDarius Cameron WilsonFrank Martin BrunkhorstJosef BriegelKonrad ReinhartMarkus LoefflerStefan KlugeAxel NierhausUlrich JaschinskiOnnen MoererAndreas WeylandPatrick Meybohmnull null

Published in: Critical care (London, England) (2018)

MR-proADM identifies disease severity and treatment response more accurately than established biomarkers and scores, adding additional information to facilitate rapid clinical decision-making and improve personalised sepsis treatment.

Keyphrases

decision making
intensive care unit
study protocol
randomized controlled trial
magnetic resonance imaging
genome wide
clinical trial
gene expression
combination therapy
sensitive detection